VIP
Vasoactive Intestinal Peptide
VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide found throughout the CNS, gut, immune system, and autonomic nervous system. Originally named for its vasodilatory properties, VIP is now understood as a master regulator of circadian rhythm, inflammation, and gut-brain axis signaling — with emerging clinical research in autoimmune and inflammatory conditions.
At a Glance
VIP acts on two receptor subtypes — VPAC1 and VPAC2 — which are expressed across nearly every tissue type. This broad receptor distribution explains VIP's involvement in seemingly disparate functions: circadian clock synchronization in the suprachiasmatic nucleus, anti-inflammatory cytokine modulation in immune tissue, vasodilation in pulmonary vasculature, and gut motility regulation.
Its role as the master synchronizer of the circadian clock's inter-cellular communication has generated substantial interest in chronobiology research — VIP is the signal that keeps individual SCN neurons in synchrony.
Phase 2 clinical trials in rheumatoid arthritis and ARDS have generated human safety and preliminary efficacy data — establishing clinical relevance beyond the extensive preclinical literature.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Circadian Clock Synchronization
Acts as the inter-neuronal synchronization signal in the SCN (suprachiasmatic nucleus) — keeping individual clock neurons in phase to maintain coherent circadian output.
Anti-Inflammatory Immunomodulation
Binds VPAC1/2 on immune cells to shift macrophage polarization toward anti-inflammatory M2 phenotype and reduce pro-inflammatory cytokine release.
Pulmonary Vasodilation
Strong vasodilatory effects in pulmonary vasculature — studied in pulmonary arterial hypertension and ARDS models.
Gut-Brain Axis Signaling
Produced by enteric neurons and regulates gut motility, secretion, and gut-immune-brain communication — a key gut-brain axis signaling molecule.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Circadian rhythm research — SCN synchronization and jet lag/shift work models
- Autoimmune disease — rheumatoid arthritis Phase 2 trials
- ARDS and pulmonary hypertension — vasodilatory and anti-inflammatory dual mechanism
- Gut-brain axis — enteric nervous system communication and gut motility
- Inflammatory bowel disease — gut immune modulation
- Neuroinflammation — CNS anti-inflammatory signaling
- Sepsis models — immune modulation in systemic inflammation
VIP's position at the intersection of circadian biology, immunology, and gut-brain axis research makes it one of the most multifunctional — and most under-recognized — research peptides available.
VIP, DSIP, and Selank each address different dimensions of CNS and immune research — with VIP uniquely positioned across both circadian and inflammatory biology.
| Aspect | VIP | DSIP | Selank |
|---|---|---|---|
| Primary CNS Role | Circadian synchronization | Delta sleep induction | Anxiolytic, anti-inflammatory |
| Immune Effects | Strong anti-inflammatory (VPAC) | HPA normalization | Tuftsin-derived immune modulation |
| Peripheral Action | Vasodilation, gut motility | Minimal | Minimal |
| Clinical Data | Phase 2 (RA, ARDS) | Small clinical trials | Russian clinical data |
| Best Research Use | Circadian, autoimmune, ARDS | Sleep architecture | Anxiety, immune |
The following reflects findings from published preclinical and clinical safety assessments where available.
Phase 2 clinical data in autoimmune and ARDS conditions — human evidence beyond preclinical
Multisystem research utility — circadian, immune, gut, and vascular research in one compound
Endogenous neuropeptide — acts through its natural receptor system; fundamental safety profile
Short half-life — rapidly degraded; research protocols require careful timing or modified delivery systems
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026